Protein detail
ALK
ALK tyrosine kinase receptor (EC 2.7.10.1) (Anaplastic lymphoma kinase) (CD antigen CD246)
Protein symbol ALK | UniProt ID | EVMP score 0.50 |
Frequency 1 | Transmembrane count 1 | Protein classification Cancer-related genesCD markersDisease related genesEnzymesFDA approved drug targetsHuman disease related genesPlasma proteinsPredicted intracellular proteinsPredicted membrane proteins |
Basic Information
Protein Names
ALK tyrosine kinase receptor (EC 2.7.10.1) (Anaplastic lymphoma kinase) (CD antigen CD246)
Protein Class
Cancer-related genesCD markersDisease related genesEnzymesFDA approved drug targetsHuman disease related genesPlasma proteinsPredicted intracellular proteinsPredicted membrane proteins
Protein Function
- Human disease related genes:Cancers:Cancers of the lung and pleura
- Human disease related genes:Cancers:Cancers of eye, brain, and central nervous system
- Predicted intracellular proteins
- ENZYME proteins:Transferases
- Cancer-related genes:Mutated cancer genes
- CD markers
- Enzymes
- Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues
- Kinases:Tyr protein kinases
- Disease related genes
- FDA approved drug targets:Small molecule drugs
Transmembrane
1039..1059; Helical
Transmembrane Count
1
Ensembl
Entrez Gene Symbol
Gene Synonym
ALK1CD246
Gene Description
ALK receptor tyrosine kinase
Chromosome
2
Position
29192774-29921586
Frequency
1
EVMP Score
0.50
Fluorescence & Localization
Tissue Specificbone marrowCell SpecificEsophageal apical cells
Function & Pathway
Protein Function
- Human disease related genes:Cancers:Cancers of the lung and pleura
- Human disease related genes:Cancers:Cancers of eye, brain, and central nervous system
- Predicted intracellular proteins
- ENZYME proteins:Transferases
- Cancer-related genes:Mutated cancer genes
- CD markers
- Enzymes
- Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues
- Kinases:Tyr protein kinases
- Disease related genes
- FDA approved drug targets:Small molecule drugs
Cellular Component
Molecular Function
KEGG
Reactome
Mediation Categories
Clinical-translation mediationReceptor-signaling mediation
Relations & Evidence
Enzyme-Mediated Modification
3 records.
| Substrate Gene Symbol | Enzyme Gene Symbol | Enzyme UniProt ID | Residue Type | Residue Offset | Modification | Database | References |
|---|---|---|---|---|---|---|---|
| ALK | HCK | P08631 | Y | 1,507 | phosphorylation | KEA | KEA:17570479 |
| ALK | IGF1R | P08069 | Y | 1,278 | phosphorylation | KEA | KEA:17570479 |
| ALK | IGF1R | P08069 | Y | 1,327 | phosphorylation | KEA | KEA:17570479 |
Ligand-Receptor Signaling
49 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| transmembrane | transmembrane | UniProt_keyword | No | No | No | Yes | No |
| transmembrane_predicted | transmembrane | OmniPath | No | No | No | Yes | No |
| transmembrane | transmembrane | GO_Intercell | No | No | No | Yes | No |
| transmembrane | transmembrane | CellPhoneDB | No | No | No | Yes | No |
| transmembrane | transmembrane | TopDB | No | No | No | Yes | No |
| transmembrane | transmembrane | LOCATE | No | No | No | Yes | No |
| transmembrane | transmembrane | Ramilowski_location | No | No | No | Yes | No |
| transmembrane | transmembrane | OmniPath | No | No | No | Yes | No |
| plasma_membrane | plasma_membrane | UniProt_location | No | No | No | Yes | No |
| plasma_membrane | plasma_membrane | Cellinker | No | No | No | Yes | No |
Regulatory Interaction Network
17 records.
Page 1 of 2Next
Protein Complex Composition
39 records.
Page 1 of 4Next
Isolation & Detection Technology
1 record.
| EV Isolation Method | Detection Method | Number of References | References |
|---|---|---|---|
| Differential UltracentrifugationSize Exclusion Chromatography | Mass spectrometry | 1 | 30875722 |
Sequence, Structure & Domains
Sequences
Length
1,620
Mass
176,442
Sequence
MGAIGLLWLLPLLLSTAAVGSGMGTGQRAGSPAAGPPLQPREPLSYSRLQRKSLAVDFVVPSLFRVYARDLLLPPSSSELKAGRPEARGSLALDCAPLLRLLGPAPGVSWTAGSPAPAEARTLSRVLKGGSVRKLRRAKQLVLELGEEAILEGCVGPPGEAAVGLLQFNLSELFSWWIRQGEGRLRIRLMPEKKASEVGREGRLSAAIRASQPRLLFQIFGTGHSSLESPTNMPSPSPDYFTWNLTWIMKDSFPFLSHRSRYGLECSFDFPCELEYSPPLHDLRNQSWSWRRIPSEEASQMDLLDGPGAERSKEMPRGSFLLLNTSADSKHTILSPWMRSSSEHCTLAVSVHRHLQPSGRYIAQLLPHNEAAREILLMPTPGKHGWTVLQGRIGRPDNPFRVALEYISSGNRSLSAVDFFALKNCSEGTSPGSKMALQSSFTCWNGTVLQLGQACDFHQDCAQGEDESQMCRKLPVGFYCNFEDGFCGWTQGTLSPHTPQWQVRTLKDARFQDHQDHALLLSTTDVPASESATVTSATFPAPIKSSPCELRMSWLIRGVLRGNVSLVLVENKTGKEQGRMVWHVAAYEGLSLWQWMVLPLLDVSDRFWLQMVAWWGQGSRAIVAFDNISISLDCYLTISGEDKILQNTAPKSRNLFERNPNKELKPGENSPRQTPIFDPTVHWLFTTCGASGPHGPTQAQCNNAYQNSNLSVEVGSEGPLKGIQIWKVPATDTYSISGYGAAGGKGGKNTMMRSHGVSVLGIFNLEKDDMLYILVGQQGEDACPSTNQLIQKVCIGENNVIEEEIRVNRSVHEWAGGGGGGGGATYVFKMKDGVPVPLIIAAGGGGRAYGAKTDTFHPERLENNSSVLGLNGNSGAAGGGGGWNDNTSLLWAGKSLQEGATGGHSCPQAMKKWGWETRGGFGGGGGGCSSGGGGGGYIGGNAASNNDPEMDGEDGVSFISPLGILYTPALKVMEGHGEVNIKHYLNCSHCEVDECHMDPESHKVICFCDHGTVLAEDGVSCIVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEAATAPGAGHYEDTILKSKNSMNQPGP
3D Structural Models
Turn
705..707; 921..923; 999..1001
Helix
698..704; 718..720; 788..794; 800..807; 896..898; 907..913; 987..989; 1087..1092; 1105..1107; 1113..1115; 1158..1173; 1204..1211; 1223..1242; 1252..1254; 1272..1280; 1288..1290; 1293..1295; 1298..1303; 1308..1323; 1335..1343; 1356..1365; 1370..1372; 1376..1388; 1390..1393
Beta Strand
675..677; 680..685; 692..694; 713..715; 724..727; 730..739; 747..751; 757..765; 770..774; 782..784; 808..810; 812..814; 825..831; 834..841; 860..862; 865..867; 875..877; 890..892; 928..930; 936..938; 956..959; 963..965; 970..975; 978..984; 990..993; 995..997; 1004..1006; 1012..1014; 1016..1022; 1096..1098; 1101..1103; 1116..1124; 1126..1135; 1137..1140; 1145..1152; 1154..1156; 1182..1186; 1188..1197; 1215..1217; 1255..1258; 1260..1263; 1266..1268; 1284..1286; 1574..1576; 1582..1584
3D Structure
Electron microscopy (2); NMR spectroscopy (5); X-ray crystallography (72)
Domain & Motif Annotations
Compositional Bias
654..666; Basic and acidic residues; 1410..1419; Basic and acidic residues
Domain (CC)
The EGF-like region drives the cytokine specificity for ALKAL2..; DOMAIN: The heparin-binding region binds heparin glycosaminoglycan (PubMed:25605972, PubMed:34646012). Heparin-binding is required for ALKAL2-driven activation (PubMed:34646012).
Domain (FT)
264..427; MAM 1; 437..473; LDL-receptor class A; 478..636; MAM 2; 1116..1392; Protein kinase
Region
48..70; Heparin-binding region; 650..674; Disordered; 987..1025; EGF-like; 1408..1463; Disordered; 1514..1540; Disordered
Protein Families
- Protein kinase superfamily
- Tyr protein kinase family
- Insulin receptor subfamily
Sequence Similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. Insulin receptor subfamily.
Clinical Relevance
Disease Involvement
Cancer-related genesDisease variantFDA approved drug targetsProto-oncogene
Related Diseases
Biomarker
Phase 1; Phase 2; Approved; Investigative; Patented
Drug Targets
FDA approved drug targets
Drugs
CERITINIBX-396CRIZOTINIBIL-10RETASPIMYCIN HYDROCHLORIDENIVOLUMABNULLALECTINIBENTRECTINIBCENISERTIBAFATINIBPEMBROLIZUMABDOXORUBICIN HYDROCHLORIDEENSARTINIBCHEMBL:CHEMBL379975TEPOTINIBCEMIPLIMAB-RWLCZOLEDRONIC ACID ANHYDROUSAPG-2449LORLATINIBVANDETANIBRIBOCICLIBVINCRISTINE SULFATEIDASANUTLINDACTOLISIBGEFITINIBDABRAFENIBNAVITOCLAXATEZOLIZUMABALK INHIBITOR ASP3026BRIGATINIBALK INHIBITOR TAE684AZD3463TOPOTECAN HYDROCHLORIDEERLOTINIBFORITINIB SUCCINATEGW441756XDINACICLIBTALETRECTINIBIPILIMUMABCARBOPLATINIFOSFAMIDETPX-0131TRAMETINIB DIMETHYL SULFOXIDEDOVITINIBTAK-715TEMOZOLOMIDEPLB1003BELIZATINIBGILTERITINIBEG5 KINESIN-RELATED MOTOR PROTEIN INHIBITOR 4SC-205RAMUCIRUMABJAK3 INHIBITOR IIDALANTERCEPTETOPOSIDESELUMETINIBSHP2 INHIBITOR PF-07284892LUMINESPIBDURVALUMABBRENTUXIMAB VEDOTINPAZOPANIBCISPLATINIRINOTECAN HYDROCHLORIDEIRUPLINALKIBPD-0166285CARBAMAZEPINEALVOCIDIBGSK-1838705ACP-547632PALBOCICLIBTOZASERTIBP53/HDM2 INTERACTION INHIBITOR CGM097REPOTRECTINIBBATOPROTAFIBCYCLOPHOSPHAMIDE ANHYDROUSCONTELTINIBPEMETREXED DISODIUMJNJ-7706621MTI-31FULVESTRANTLINIFANIBMETHOTREXATEFILGOTINIBDEXAMETHASONEMILADEMETANRG-1530CRENOLANIBONALESPIBIXAZOMIBTAMATINIBILORASERTIBHESPERADINALK/C-MET INHIBITOR TQ-B3139ALK/TRK INHIBITOR TSR-011OSIMERTINIBBEVACIZUMAB-AWWBCYTARABINEHJC0152SARACATINIBALECTINIB HYDROCHLORIDEASP-3026IMATINIBTREMELIMUMABVENETOCLAXTHZ1CHEMBL:CHEMBL1997335CHEMBL:CHEMBL546797PF-562271GANETESPIBALK INHIBITOR NVL-655CEDIRANIBFICONALKIBNVP-TAE 226CEP-37440OCTREOTIDE ACETATESIROLIMUS
Antibody
Interaction Protein
ENSG00000165731
Interaction Count
1
Interaction Dataset
intact_biogrid